ArticleThe Journal of infection2018
Human protective monoclonal antibodies against the HA stem of group 2 HAs derived from an H3N2 virus-infected human.
Article in The Journal of infection, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Review
- Disease diagnostics using machine learning of B cell and T cell receptor sequences.Science (New York, N.Y.) · 2025Article
- Article
- Identification of hub genes and therapeutic drugs in rheumatoid arthritis patients.Clinical rheumatology · 2021Article
- Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus.Nature microbiology · 2019Article
- Article
- Characterization of Mouse Monoclonal Antibodies Against the HA of A(H7N9) Influenza Virus.Viruses · 2019Article
- Structure-function analysis of neutralizing antibodies to H7N9 influenza from naturally infected humans.Nature microbiology · 2019Article
- Differences in the ease with which mutant viruses escape from human monoclonal antibodies against the HA stem of influenza A virus.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesBroadly reactive human monoclonal antibodies against the HA stem of influenza A virus are being developed as therapeutic agents as well as to understand the epitopes that are essential for a universal influenza virus vaccine.
methodsWe isolated and characterized two hetero-reactive human monoclonal antibodies from an H3N2 virus-infected human.
resultsThese antibodies, which are predominantly bound to the HA stem of group 2 HAs, used IGHV3-66 and IGHV4-38-2 germline genes, respectively. They possessed in vitro neutralizing ability, and in vivo protective efficacy against lethal infection with H3N2 or H7N9 virus. Escape mutations revealed that one of the protective antibodies recognized the α-helix A of HA2, and the other recognized the C-terminal portion of the fusion peptide and the β-sheet that precedes the α-helix A of HA2.
conclusionsOf many human protective monoclonal antibodies against the HA stem, two human protective monoclonal antibodies were isolated in this study that predominantly recognize epitopes on the HA stem of group 2 and use unique IGHV3-66 and IGHV4-38-2 germline genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.